Future Fund LLC Raises Stock Holdings in Natera, Inc. $NTRA

Future Fund LLC increased its stake in Natera, Inc. (NASDAQ:NTRA) by 26.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,881 shares of the medical research company’s stock after purchasing an additional 3,580 shares during the period. Natera makes up approximately 1.2% of Future Fund LLC’s portfolio, making the stock its 28th biggest holding. Future Fund LLC’s holdings in Natera were worth $3,376,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Integrated Wealth Concepts LLC grew its stake in Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its holdings in shares of Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after acquiring an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Natera during the 2nd quarter worth $298,000. Finally, WINTON GROUP Ltd purchased a new position in Natera in the second quarter worth $558,000. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Up 0.6%

Shares of NASDAQ:NTRA opened at $271.39 on Friday. The stock has a market cap of $38.87 billion, a PE ratio of -166.50 and a beta of 1.51. The company’s fifty day moving average is $233.97 and its 200 day moving average is $220.41. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04.

Analysts Set New Price Targets

A number of research analysts recently commented on NTRA shares. Wells Fargo & Company increased their target price on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. TD Cowen reiterated a “buy” rating on shares of Natera in a report on Wednesday. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Natera in a report on Monday, July 6th. Barclays reduced their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 24th. Finally, The Goldman Sachs Group initiated coverage on Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Insider Buying and Selling at Natera

In other news, Director Rowan E. Chapman sold 2,964 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the transaction, the director directly owned 3,124 shares of the company’s stock, valued at approximately $677,220.72. This trade represents a 48.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 178,872 shares of company stock valued at $39,627,696. 5.05% of the stock is currently owned by insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.